ASCO Daily News cover art

All Episodes

ASCO Daily News — 100 episodes

#
Title
1

'No Margin for Error': What to Know Before Implementing AI in Clinical Practice

2

Groundbreaking Results Shift Treatment Paradigm in High-Risk Smoldering Multiple Myeloma

3

Navigating Therapeutic Advances in EGFR-Mutated NSCLC

4

Highlights From the 2026 ASCO GU Cancers Symposium

5

Personalizing Treatment in Head and Neck Cancers

6

Can Low-Dose Immunotherapy Expand Global Access to Cancer Care?

7

Highlights From the 2026 ASCO GI Cancers Symposium

8

Expanding Treatment Options for Breast Cancer: ADCs and Oral SERDs

9

What Challenges Will Oncologists Face in 2026?

10

What Frontline Treatment Should Be Used in Advanced Ovarian Cancer?

11

Managing Immune-Related Toxicities in Oncology

12

Key Takeaways From the 2025 ASCO Quality Care Symposium

13

Identifying Young BRCA Carriers With Breast Cancer: Early Detection Can Lead to Better Prognosis

14

Cancer and Aging: Researching the Path to Longer, More Vibrant Lives

15

Promising New Therapies in Non-Muscle Invasive Bladder Cancer

16

The Gut Microbiome and Immunotherapy: Researching the Connection

17

Why Are Early-Onset GI Cancers on the Rise?

18

What Is Precision Palliative Care? Rethinking a Care Delivery Problem

19

From Clinic to Clinical Trials: Responsible AI Integration in Oncology

20

Immunotherapy at ASCO25: Drug Development, Melanoma Treatment, and More

21

Innovations in GU Cancer Treatment at ASCO25

22

What Lung Cancer Abstracts Stood Out at ASCO25?

23

GI Cancer Research at ASCO25: Plenary Highlights and More

24

Breast Cancer Research Poised to Change Practice From ASCO25

25

Precision Oncology Advances in Hematologic Cancers at ASCO25

26

ASCO25 Recap: CHALLENGE, DESTINY-Breast09, and More

27

Day 5: Top Takeaways From ASCO25

28

Day 4: Top Takeaways from ASCO25

29

Day 3: Top Takeaways From ASCO25

30

Day 2: Top Takeaways From ASCO25

31

Day 1: Top Takeaways From ASCO25

32

ASCO25 Preview: Key Research Accelerating Cancer Care

33

Optimizing Oncology Clinical Pathways at the Point of Care

34

Personalizing Lung Cancer Management With ctDNA: Where We Are and Where We Are Headed

35

The Evolving Role of Precision Surgery in Gynecologic Cancers

36

Emerging Therapies in Acute Myeloid Leukemia

37

Practice-Informing Research Across GU Oncology: Highlights From GU25

38

Therapeutic Advances Across GI Cancers: Highlights From GI25

39

Advances in Adjuvant Therapy for High-Risk Early Breast Cancer With Germline Mutations

40

How to Advance Cancer Care for Native Americans

41

What Challenges Will Oncologists Face in 2025?

42

A New Standard of Care for Cervical Cancer: Assessing the KEYNOTE-A18 Study

43

Advances in Immunotherapy for Melanoma and Beyond

44

Personalizing Locoregional Treatment for Breast Cancer

45

How Are Cancer Centers Navigating IV Fluid Shortages and the Devastation of Hurricane Season?

46

Key Takeaways From the 2024 ASCO Quality Care Symposium

47

Key Takeaways From 2024 ASCO Breakthrough

48

How AI Can Improve Patient Identification and Recruitment for Clinical Trials

49

DESTINY-Breast06 and A-BRAVE: Advances in Breast Cancer Research

50

The Risks and Benefits of Taking a Break From Cancer Treatment

51

How to Enhance Early-Stage Breast Cancer Survivorship

52

Putting Patients First: Common Sense in Cancer Care

53

An Era of Promise for Cancer Vaccines

54

GU Oncology Highlights From ASCO24

55

Top ASCO24 Abstracts That Could Revolutionize Oncology

56

Enhancing Treatment Efficacy in Multiple Myeloma at ASCO24

57

ASCO24: Transforming the Lung Cancer Treatment Landscape

58

ESOPEC and Other Key GI Studies at ASCO24

59

Immunotherapy at ASCO24: NADINA and Other Key Studies

60

Day 4: Top Takeaways From ASCO24

61

Day 3: Top Takeaways From ASCO24

62

Day 2: Top Takeaways From ASCO24

63

Day 1: Top Takeaways From ASCO24

64

Key Abstracts in GU Cancers at ASCO24

65

Exploring CAR T Cells in GI Cancers at ASCO24

66

ASCO24: The Future of Personalized Immunotherapy

67

Novel Approaches in Hematologic Malignancies at ASCO24

68

ASCO24: The Era of the ADCs in NSCLC

69

Spotlight on Breast Cancer at ASCO24

70

Optimizing Novel Therapies and Surgery in Early-Stage NSCLC

71

A Revolution in Immunotherapy for Cervical and Endometrial Cancers

72

How ctDNA Is Advancing Care for Patients With GI Cancers

73

New Machine Learning Framework Uses EHR Data to Assess ICI Effectiveness, Toxicity

74

Innovations in CAR T-Cell Therapy for Multiple Myeloma

75

ADCs in Breast Cancer: Sequencing, Resistance, and Managing Toxicity

76

Advances in Precision Oncology for GI Cancers at GI24

77

Key Advances in Prostate, Kidney, and Bladder Cancers at GU24

78

What's New in Prostate Cancer, RCC, and mUC at GU24

79

Celebrating 20 Years of Evolution in GU Oncology

80

What the FDA CAR T-Cell Therapy Investigation Means for Oncologists

81

Managing the Complexities of Oncology Practice in 2024

82

Solutions and Key Research to Advance High-Quality Cancer Care

83

How to Implement Universal Germline Testing for CRC

84

Changing the Gut Microbiome to Improve the Efficacy of Immunotherapy

85

Navigating the Complexities of Next-Generation Endocrine Therapy in HR+ Breast Cancer

86

ASCO Breakthrough: Scientific Innovations and Emerging Technologies in Cancer Care

87

How Oncologists Are Confronting the Cancer Drug Shortage

88

AI Will Allow Doctors to Reclaim Time With Patients

89

Managing the Side Effects of Endocrine Therapy for Breast Cancer

90

The Emergence of Triplet Therapies in ccRCC in the Frontline Setting

91

Novel Therapies in GI Oncology at ASCO23

92

THOR, CONTACT-03, and Other Advances in GU Cancers at ASCO23

93

Spotlight on Immunotherapy at ASCO23

94

Highlights in Hematologic Malignancies at ASCO23

95

ADAURA, KEYNOTE-671, and Other Key Advances in Lung Cancer at ASCO23

96

SONIA, NATALEE, and Other Advances in Breast Cancer at ASCO23

97

Addressing the Impact of Prior Authorization on Access to Cancer Treatment

98

ASCO23: RELATIVITY-047, CheckMate-038, and Other Advances in Immunotherapy

99

ASCO23: COMMANDS, CAPTIVATE, and Key Studies in Hematologic Malignancies

100

ASCO23: Novel Approaches in RCC, mUC, and Prostate Cancer